Jing Zhou1, Hsan-Au Wu2, Linda Saxe Einbond3,4,5, Emeka Mbazor1, Guiyun Song6, Michael Balick7,1, James A DeVoti8, Stephen Redenti1, Mario R Castellanos9,10. 1. Lehman College and the Graduate Center, City University of New York, New York, NY, 10468, USA. 2. Columbia University College of Physicians and Surgeons, New York, NY, 10032, USA. 3. The New York Botanical Garden, Bronx, NY, 10458, USA. lseinbond@gmail.com. 4. Lehman College and the Graduate Center, City University of New York, New York, NY, 10468, USA. lseinbond@gmail.com. 5. Columbia University College of Physicians and Surgeons, New York, NY, 10032, USA. lseinbond@gmail.com. 6. R&D Department, Professional Compounding Centers of America, Houston, TX, 77099, USA. 7. The New York Botanical Garden, Bronx, NY, 10458, USA. 8. The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, 11030, USA. 9. Innovene Therapeutics, Brooklyn, NY, 11230, USA. 10. Staten Island University Hospital, Northwell Health, Staten Island, NY, 10305, USA.
Abstract
BACKGROUND: The phytochemical mixture TriCurin (curcumin, epigallocatechin gallate (EGCG) and resveratrol) eliminates human papillomavirus (HPV) (+) cancer cells in vitro and in vivo. In this study, we further evaluate TriCurin. METHODS: The activity of TriCurin and its individual compounds was assayed on W12 cells, derived from a cervical precancer containing episomal and integrated HPV16 DNA, using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays, microscopy and reverse transcription-polymerase chain reaction (RT-PCR), and on HeLa cells by gene expression analysis. The stability and toxicity of TriCurin microemulsion were tested in an organotypic cervical tissue model. RESULTS: TriCurin and its individual compounds inhibit the growth of W12 cells, episomal, type 1 and 2 integrants; the relative order of activity is TriCurin, EGCG, curcumin, or resveratrol. RT-PCR shows that TriCurin activates p53 and suppresses HPV16 mRNAs E1, E2, E4, E6 and E7 at 24 h in W12 cells. Gene expression analysis shows that TriCurin activates pro-apoptotic genes and represses anti-apoptotic genes in HeLa cells. TriCurin in a microemulsion is stable and non-toxic to cervical tissue. The combination of TriCurin and tanshinone IIA exhibits additional synergy against HeLa cells. CONCLUSIONS: TriCurin, and the combination of TriCurin with tanshinone IIA, are effective against HPV (+) cells. The phytochemical mixture, in the microemulsion-based cream, is a promising therapeutic for the prevention and treatment of cervical cancer.
BACKGROUND: The phytochemical mixture TriCurin (curcumin, epigallocatechin gallate (EGCG) and resveratrol) eliminates human papillomavirus (HPV) (+) cancer cells in vitro and in vivo. In this study, we further evaluate TriCurin. METHODS: The activity of TriCurin and its individual compounds was assayed on W12 cells, derived from a cervical precancer containing episomal and integrated HPV16 DNA, using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays, microscopy and reverse transcription-polymerase chain reaction (RT-PCR), and on HeLa cells by gene expression analysis. The stability and toxicity of TriCurin microemulsion were tested in an organotypic cervical tissue model. RESULTS:TriCurin and its individual compounds inhibit the growth of W12 cells, episomal, type 1 and 2 integrants; the relative order of activity is TriCurin, EGCG, curcumin, or resveratrol. RT-PCR shows that TriCurin activates p53 and suppresses HPV16 mRNAs E1, E2, E4, E6 and E7 at 24 h in W12 cells. Gene expression analysis shows that TriCurin activates pro-apoptotic genes and represses anti-apoptotic genes in HeLa cells. TriCurin in a microemulsion is stable and non-toxic to cervical tissue. The combination of TriCurin and tanshinone IIA exhibits additional synergy against HeLa cells. CONCLUSIONS:TriCurin, and the combination of TriCurin with tanshinone IIA, are effective against HPV (+) cells. The phytochemical mixture, in the microemulsion-based cream, is a promising therapeutic for the prevention and treatment of cervical cancer.
Authors: William Alazawi; Mark Pett; Barbara Arch; Laurie Scott; Tom Freeman; Margaret A Stanley; Nicholas Coleman Journal: Cancer Res Date: 2002-12-01 Impact factor: 12.701
Authors: Xiao-Hong Li; Kristine C Y McGrath; Van H Tran; Yi-Ming Li; Sravan Mandadi; Colin C Duke; Alison K Heather; Basil D Roufogalis Journal: Evid Based Complement Alternat Med Date: 2013-07-17 Impact factor: 2.629